IDXX vs TMO vs MRK Stock Comparison

Idexx Laboratories, Thermo Fisher Scientific and Merck Prices as of Nov 13, 2026 Peers: Industry group
MRK Merck & Co., Inc.
$147.78 +0.3% 1M +59.0% 1Y
Market cap
$357.22B
P/E
145.6x
Revenue (TTM)
$67.38B
Div. yield
0.02%
Pharmaceuticals Healthcare
5 wins

Head to Head

12 decided of 12

Merck leads on 5 of the 12 questions below (Merck 5, Idexx Laboratories 5, Thermo Fisher Scientific 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionIDXXTMOMRKLeader
Larger companyMarket capitalisation $55.34B $255.60B $357.22B MRK
Cheaper on earningsLower P/E, profitable companies only 46.8x 36.1x 145.6x TMO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 44.6x 27.0x 56.6x TMO
Faster revenue growthRevenue growth, trailing twelve months +11.9% +8.3% +4.9% IDXX
More profitableNet margin, trailing twelve months 25.4% 14.9% 3.6% IDXX
Better return on capitalReturn on invested capital 45.4% 8.0% 2.5% IDXX
Less leveragedLower net debt / EBITDA 0.4x 3.1x 3.6x IDXX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.02% MRK
Better 1-year returnPrice return, last 12 months +0.4% +20.7% +59.0% MRK
Better 5-year returnAnnualised price return, 5 years +2.3%/yr +2.0%/yr +12.0%/yr MRK
Less volatileAnnualised volatility, 1 year 36.2% 30.7% 29.6% MRK
Higher overall scoreMean of the five percentile scores vs peers 76/100 60/100 61/100 IDXX

Percentile Scorecard

IDXXTMOMRK

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisIDXXTMOMRK
Valuation 74 #175 of 660 62 #94 of 243 85 #97 of 660
Growth 70 #184 of 619 41 #136 of 228 30 #434 of 619
Profitability 98 #12 of 595 82 #40 of 222 90 #59 of 595
Financial Health 46 #371 of 683 31 #172 of 248 21 #538 of 683
Shareholder Returns 94 #30 of 459 82 #29 of 158 79 #98 of 459
Overall 76 60 61
  • IDXX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • TMO ranked among 252 companies in Medical Devices and Diagnostics
  • MRK ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodIDXXTMOMRKSPY
1 month +33.1%+4.0%+0.3% -2.0%
3 months +27.8%+19.1%+8.8% -2.8%
6 months +33.2%+59.7%+32.7% +2.0%
Year to date +4.1%+20.8%+40.4% +10.6%
1 year +0.4%+20.7%+59.0% +12.2%
3 years +55.0%+52.5%+44.6% +68.1%
3 years, per year +15.7%+15.1%+13.1% +18.9%
5 years +12.1%+10.2%+75.9% +61.4%
5 years, per year +2.3%+2.0%+12.0% +10.1%
10 years +545.1%+362.9%+131.1% +248.5%
10 years, per year +20.5%+16.6%+8.7% +13.3%

Risk

MeasureIDXXTMOMRKSPY
Volatility, 1Y 36.2%30.7%29.6% 13.6%
Downside volatility, 1Y 32.6%29.2%24.1% 13.9%
Beta vs S&P 500, 1Y 0.840.710.20 1.00
Return / volatility, 1Y 0.010.671.99 0.90
Max drawdown, 5Y -50.9%-41.5%-44.7% -25.4%
From 52-week high -8.1%-3.0%-5.5% -3.2%
52-week high $766.68$721.63$156.45 $779.14
52-week low $504.70$438.34$92.86 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleIDXXTMOMRK
P/E now vs peer median 47.0xmedian 17.0x 36.6xmedian 26.5x 148.7xmedian 17.0x
P/S now vs peer median 11.9xmedian 8.4x 5.5xmedian 2.7x 5.4xmedian 8.4x
EV/EBITDA now vs peer median 33.7xmedian 14.6x 25.5xmedian 18.4x 33.7xmedian 14.6x
P/FCF now vs peer median 42.6xmedian 19.0x 34.2xmedian 25.4x 24.7xmedian 19.0x
P/B now vs peer median 29.7xmedian 2.0x 4.7xmedian 2.5x 8.1xmedian 2.0x
PEG now vs peer median 3.10median 0.43 4.84median 0.98 -8.16median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsIDXXTMOMRK
Revenue $4.66B $47.35B $67.38B
Gross profit $2.92B $19.45B $48.35B
Operating income $1.51B $8.47B $4.76B
Net income $1.18B $7.09B $2.45B
Free cash flow $1.30B $7.60B $14.75B
R&D $266.87M $1.40B $30.76B
EPS (diluted) $14.96 $19.06 $0.99
Cash & equivalents $197.54M $5.46B $9.55B
Total debt $848.88M $41.37B $53.78B
Shares (diluted) 79.05M 371.00M 2.48B
Enterprise value $54.56B $232.12B $320.16B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricIDXXTMOMRK
P/E 47.0x 36.6x 148.7x
P/FCF 42.6x 34.2x 24.7x
P/Operating cash flow 39.1x 27.8x 19.5x
P/S 11.9x 5.5x 5.4x
P/B 29.7x 4.7x 8.1x
P/Tangible book 31.7x 7.1x 17.8x
EV/EBITDA 33.7x 25.5x 33.7x
EV/EBIT 37.3x 34.8x 85.8x
EV/Revenue 12.0x 6.2x 6.1x
EV/FCF 43.1x 38.8x 27.7x
EV/Operating cash flow 39.6x 31.6x 21.8x
PEG (3Y EPS CAGR) 3.10 4.84 -8.16

Growth

14 metrics
MetricIDXXTMOMRK
Revenue growth (1Y) 11.9% 8.3% 4.9%
Revenue CAGR (3Y) 9.1% 2.9% 4.3%
Gross profit growth (1Y) 13.7% 7.8% -2.5%
Gross profit CAGR (3Y) 10.8% 4.0% 3.8%
Operating income growth (1Y) 15.3% 12.8% -78.2%
Operating income CAGR (3Y) 11.8% 7.2% -13.9%
Net income growth (1Y) 15.1% 7.9% -87.1%
Net income CAGR (3Y) 12.8% 6.2% -19.1%
EPS growth (1Y) 17.4% 9.7% -87.0%
EPS CAGR (3Y) 15.1% 7.6% -18.2%
Operating cash flow growth (1Y) 30.4% 21.9% 9.6%
Operating cash flow CAGR (3Y) 19.6% 4.5% 2.9%
Free cash flow growth (1Y) 35.3% 24.3% 13.0%
Free cash flow CAGR (3Y) 24.2% 5.1% 3.8%

Profitability

14 metrics
MetricIDXXTMOMRK
Gross margin 62.7% 41.1% 71.8%
EBITDA margin 35.7% 24.4% 18.0%
Operating margin 32.3% 17.9% 7.1%
Pretax margin 31.7% 16.7% 7.1%
Net margin 25.4% 14.9% 3.6%
FCF margin 28.0% 16.0% 21.9%
Operating cash flow margin 30.4% 19.7% 27.8%
Return on equity 67.9% 13.2% 5.6%
Return on assets 33.1% 6.2% 1.9%
Return on invested capital 45.4% 8.0% 2.5%
Return on capital employed 65.2% 8.5% 4.6%
Asset turnover 1.3x 0.4x 0.5x
Cash conversion (OCF / net income) 1.2x 1.3x 7.6x
Stock comp / revenue 1.4% 0.7% 1.6%

Financial Health

11 metrics
MetricIDXXTMOMRK
Debt / assets 22.9% 36.2% 40.5%
Debt / equity 0.5x 0.8x 1.2x
Net debt / EBITDA 0.4x 3.1x 3.6x
Debt / FCF 0.7x 5.4x 3.6x
Liabilities / assets 49.6% 52.1% 66.1%
Equity / assets 50.4% 47.9% 33.9%
Interest coverage 43.5x 12.0x –
Current ratio 1.2x 1.8x 1.4x
Quick ratio 0.7x 1.2x 0.8x
Cash ratio 0.2x 0.4x 0.3x
Altman Z-score 23.56 4.18 3.90

Shareholder Returns

7 metrics
MetricIDXXTMOMRK
Dividend yield – 0.3% 2.3%
Net buyback yield 1.7% 1.6% 0.8%
Shareholder yield 1.7% 1.8% 3.1%
Payout ratio (earnings) – 9.5% 341.6%
Payout ratio (FCF) – 8.9% 56.7%
Dividend growth (1Y) – 8.0% 3.2%
Dividend CAGR (3Y) – 10.1% 4.4%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusIDXXTMOMRK
Forward P/E 44.6xFY2026 27.0xFY2026 56.6xFY2026
EPS, next fiscal year $15.78FY2026 $25.92FY2026 $2.61FY2026
EPS growth, next FY +20.6%FY2026 +13.3%FY2026 -70.9%FY2026
EPS growth, the year after +12.3% +2.2% +228.7%
Revenue, next fiscal year $5.03BFY2026 $50.12BFY2026 $69.66BFY2026
Revenue growth, next FY +17.0%FY2026 +12.5%FY2026 +7.2%FY2026
Revenue growth, the year after +0.4% -2.7% -4.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersIDXXTMOMRK
Held by institutions 93.6% 90.2% 79.9%
Institutions holding 1,292 2,627 3,804
Change in shares held, QoQ +4.1% +0.8% +2.6%
Institutions buying 590 1,145 1,844
Institutions selling 496 1,145 1,469
Buyers to sellers 1.19 1.00 1.26

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

IDXXTMOMRK
IDXX 1.00 0.29 0.15
TMO 0.29 1.00 0.18
MRK 0.15 0.18 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, IDXX, TMO and MRK?

Merck (MRK) is the largest by market capitalisation: Idexx Laboratories (IDXX) $55.34B, Thermo Fisher Scientific (TMO) $255.60B, Merck (MRK) $357.22B.

Which stock is cheaper, IDXX, TMO and MRK?

Thermo Fisher Scientific (TMO) trades on the lowest price-to-earnings ratio (Idexx Laboratories (IDXX) 46.8x, Thermo Fisher Scientific (TMO) 36.1x, Merck (MRK) 145.6x). On next year's consensus earnings, Thermo Fisher Scientific (TMO) is cheapest (Idexx Laboratories (IDXX) 44.6x, Thermo Fisher Scientific (TMO) 27.0x, Merck (MRK) 56.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Idexx Laboratories (IDXX) grew revenue fastest over the trailing twelve months: Idexx Laboratories (IDXX) +11.9%, Thermo Fisher Scientific (TMO) +8.3%, Merck (MRK) +4.9%.

Which company is more profitable?

Idexx Laboratories (IDXX) has the highest net margin (Idexx Laboratories (IDXX) 25.4%, Thermo Fisher Scientific (TMO) 14.9%, Merck (MRK) 3.6%). On return on invested capital, Idexx Laboratories (IDXX) leads (Idexx Laboratories (IDXX) 45.4%, Thermo Fisher Scientific (TMO) 8.0%, Merck (MRK) 2.5%).

Which stock has performed better?

Over the past year Merck (MRK) returned the most: Idexx Laboratories (IDXX) +0.4%, Thermo Fisher Scientific (TMO) +20.7%, Merck (MRK) +59.0%. Over five years, Merck (MRK) compounded fastest (Idexx Laboratories (IDXX) +2.3%/yr, Thermo Fisher Scientific (TMO) +2.0%/yr, Merck (MRK) +12.0%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Merck (MRK) has the highest dividend yield: Idexx Laboratories (IDXX) 0.00%, Thermo Fisher Scientific (TMO) 0.00%, Merck (MRK) 0.02%. Idexx Laboratories (IDXX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Merck (MRK) has been the steadiest (Idexx Laboratories (IDXX) 36.2%, Thermo Fisher Scientific (TMO) 30.7%, Merck (MRK) 29.6%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, IDXX, TMO and MRK?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Merck (MRK) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.